Pancreatic cancer: Stroma and its current and emerging targeted therapies

Janaiah Kota, Julie Hancock, Jason Kwon, Murray Korc

Research output: Contribution to journalShort survey

52 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is a major obstacle for drug delivery to the tumor bed and plays a crucial role in pancreatic cancer progression. Targeting stroma is considered as a potential therapeutic strategy to improve anti-cancer drug efficacy and patient survival. Although numerous stromal depletion therapies have reached the clinic, they add little to overall survival and are often associated with toxicity. Furthermore, increasing evidence suggests the anti-tumor properties of stroma. Its complete ablation enhanced tumor progression and reduced survival. Consequently, efforts are now focused on developing stromal-targeted therapies that normalize the reactive stroma and avoid the extremes: stromal abundance vs. complete depletion. In this review, we summarized the state of current and emerging anti-stromal targeted therapies, with major emphasis on the role of miRNAs in PDAC stroma and their potential use as novel therapeutic agents to modulate PDAC tumor-stromal interactions.

Original languageEnglish (US)
Pages (from-to)38-49
Number of pages12
JournalCancer Letters
Volume391
DOIs
StatePublished - Apr 10 2017

    Fingerprint

Keywords

  • Pancreatic Cancer
  • Stroma
  • Targeted therapies
  • Tumor microenvironment
  • miRNAS

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this